DrugPatentWatch Database Preview
CAMBIA Drug Profile
Which patents cover Cambia, and when can generic versions of Cambia launch?
Cambia is a drug marketed by Assertio and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-one patent family members in twenty-two countries.
The generic ingredient in CAMBIA is diclofenac potassium. There are forty-seven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.
Summary for CAMBIA
| International Patents: | 31 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 43 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,254 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CAMBIA |
| Drug Sales Revenues: | Drug sales revenues for CAMBIA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CAMBIA |
| DailyMed Link: | CAMBIA at DailyMed |
Recent Clinical Trials for CAMBIA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Scripps Health | Phase 4 |
| Depomed | Phase 4 |
| Mayo Clinic | Phase 2/Phase 3 |
Recent Litigation for CAMBIA
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC | 2012-02-27 |
| NAUTILUS NEUROSCIENCES, INC. v. EDICT PHARMACEUTICALS PVT. LTD. | 2011-07-20 |
| NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC |
Pharmacology for CAMBIA
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
| Physiological Effect | Decreased Prostaglandin Production |
Synonyms for CAMBIA
| 15307-81-0 |
| 15307-86-5 (Parent) |
| 2-((2,6-dichlorophenyl)amino)benzeneacetic acid, monopotassium salt |
| AB0013318 |
| AC-18735 |
| AKOS015889752 |
| AKOS015994733 |
| AN-8291 |
| Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, monopotassium salt |
| C14H10Cl2KNO2 |
| C14H10Cl2NO2.K |
| Cambia (TN) |
| Cataflam |
| Cataflam (TN) |
| CGP 45840B |
| CGP-45840B |
| CHEBI:4508 |
| CHEMBL1200804 |
| D00903 |
| Diclofenac potassium |
| Diclofenac potassium (USAN) |
| Diclofenac potassium [USAN:USP] |
| Diclofenac potassium [USAN] |
| DTXSID30165212 |
| FT-0603076 |
| H866 |
| HMS3656D18 |
| I01-3215 |
| KS-5037 |
| KXZOIWWTXOCYKR-UHFFFAOYSA-M |
| L4D5UA6CB4 |
| LS-173441 |
| MolPort-005-937-655 |
| Potassium (o-(2,6-dichloroanilino)phenyl)acetate |
| potassium {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
| potassium 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate |
| potassium 2-(2-(2,6-dichlorophenylamino)phenyl)acetate |
| potassium 2-[2-(2,6-dichloroanilino)phenyl]acetate |
| potassium;2-[2-(2,6-dichloroanilino)phenyl]acetate |
| PubChem5895 |
| s3062 |
| SC-01315 |
| SCHEMBL40784 |
| SW196404-4 |
| UNII-L4D5UA6CB4 |
| Voltfast |
| Zipsor |
| Zipsor (TN) |
Paragraph IV (Patent) Challenges for CAMBIA
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| CAMBIA | FOR SOLUTION;ORAL | diclofenac potassium | 022165 | 2011-01-24 |
US Patents and Regulatory Information for CAMBIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAMBIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | Start Trial | Start Trial |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAMBIA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101352130 | Start Trial |
| Mexico | 2007016072 | Start Trial |
| Canada | 2632375 | Start Trial |
| Hong Kong | 1213814 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
